Theresa Redling, DO
Geriatric Medicine · Livingston, NJNPI 1295840379
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 44.4% of the total. Reporting peaked in 2024 at $3,792 and has fallen 79.2% since, to $790 in 2025. Among geriatric medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Pfizer$370
- Avanir Pharmaceuticals, Inc.$307
- Lilly USA, LLC$302
- Eisai Inc.$292
- Sumitomo Pharma America, Inc.$264
- plus $2K from 34 others
What the payments were for
- Consulting fees$2,05528%
- Travel & lodging$84512%
- Food & beverage$4,22158%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,216 in reported general payments places this provider in the 95th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 124 | $143,161 |
| MyrbetriqMirabegron | 110 | $78,123 |
| JardianceEmpagliflozin | 51 | $46,079 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $28,668 |
| JanuviaSitagliptin Phosphate | 18 | $26,315 |
| XareltoRivaroxaban | 11 | $13,478 |
| RybelsusSemaglutide | 14 | $13,041 |
| LinzessLinaclotide | 14 | $12,066 |
| GemtesaVibegron | 13 | $11,223 |
| TrulicityDulaglutide | 14 | $10,770 |
| OzempicSemaglutide | 11 | $10,278 |
| EntrestoSacubitril/Valsartan | 15 | $10,106 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,737 |
| Epinephrine | 16 | $5,399 |
| Memantine Hcl | 87 | $4,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $370 | $143,161124 claims |
| Astellas Pharma US IncMyrbetriq | $136 | $78,123110 claims |
| Boehringer IngelheimJardiance | $57 | $46,07951 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $16 | $36,40445 claims |
| MerckJanuvia | $209 | $26,31518 claims |
| Novo NordiskRybelsus, Ozempic | $17 | $23,31925 claims |
| AbbVieLinzess, Synthroid | $198 | $14,40642 claims |
| Johnson & JohnsonXarelto | $89 | $13,47811 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $264 | $11,22313 claims |
| Lilly USA, LLCTrulicity | $302 | $10,77014 claims |
| NovartisEntresto | $108 | $10,10615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in Livingston
- Emily BahlerLivingston$3K
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Joshua Shua HaimManchester$45K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Sarita RastogiHackensack$7K
- Leslie FeiginDenville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.